BioSpace News Archive

According to Report, the Clinical Trial Supplies market size is estimated to surpass around US$ 13.3 billion by 2030 and is expected to registered growth at a CAGR of 17.3% from 2021 to 2030.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced the departure of Scott Leffler, Sotera Health’s Chief Financial Officer.

The global Clinical Trial Kits market size is expected to be worth around US$ 5.1 billion by 2030, according to a new report by Vision Research Reports.

POINT Biopharma Global Inc. announced that the Company’s Chief Executive Officer, Dr. Joe McCann, will participate in the following upcoming investor conferences.

Increasing prevalence of chronic health conditions, rising demand for personalized medicine, and growing preference for outsourcing services are some key factors expected to drive global Bioanalytical Testing Service market growth.

Increasing prevalence of various types of cancers worldwide, rising number of clinical trials and preclinical studies on oncolytic virus, and increasing investments in research and development of advanced cancer therapies are some key factors expected to drive global Oncolytic Virus Therapy market growth.

Increasing awareness about early cancer diagnosis, rising prevalence of various types of cancers, and growing demand for precision medicine are some factors expected to drive global tumor genomics market growth.

Evofem Biosciences, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)” at the Society for Investigative Dermatology 2022 Annual Meeting.